All In Biotech

Drug Trial Radar · NCT06417775

Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine With an Open-Label Extension

Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 496 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

496

Planned (sponsor's estimate)

Start

Sep 10, 2024

Primary completion

Nov 2027

Study completion Nov 2027

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
May 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A migraine is a moderate to severe headache typically on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. Menstrual migraine (MM) is defined as migraine attacks that occur within the perimenstrual period (PMP) in at least 2 out of 3 menstrual cycles. The PMP is from 2 days before the onset of menstrual bleeding to 2 days after. This study will assess how safe and effective ubrogepant is in treating menstrual migraine. Adverse Events and change in disease activity will be assessed. Ubrogepant is an investigational drug being developed for short-term prevention of menstrual migraine. Participants will be randomly assigned to one of the 2 groups to receive either ubrogepant or placebo. Around 496 adult female participants with menstrual migraine will be enrolled in approximately 100 sites in the United States and Puerto Rico. Participants will receive oral ubrogepant tablets once daily for 7 consecutive days starting 3 days prior to estimated onset of menses per cycle for 3 PMPs during double-blind period (16 weeks). Eligible participants may continue to receive oral ubrogepant tablets once daily for 7 consecutive days per cycle starting 3 days prior to estimated onset of menses during open-label extension period (52 weeks). There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will collect data daily in electronic diaries and attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

  • Migraine

Interventions

  • UbrogepantDrug

    Oral Tablets

  • Placebo for UbrogepantDrug

    Oral Tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Number of Migraine Days Occurring During Perimenstrual Periods (PMPs) Across the Double-Blind Treatment PeriodTime frame: Up to approximately 16 Weeks
  2. Number of Participants With Adverse Events (AEs)Time frame: Up to approximately 68 Weeks

Locations

106 sites in 2 countries. Site status is shown where the registry gives one.

  • Central Research Associates /ID# 260161

    Birmingham, Alabama

  • Rehabilitation and Neurological Services /ID# 275593

    Huntsville, Alabama

  • MD First Research - Chandler /ID# 262564

    Chandler, Arizona

  • Gilbert Neurology /ID# 260179

    Gilbert, Arizona

  • Foothills Research Center/CCT Research /ID# 260180

    Phoenix, Arizona

  • Trialmed-Synexus Clinical Research US, Inc. - Tucson /ID# 258309

    Tucson, Arizona

  • Preferred Research Partners /ID# 262786

    Little Rock, Arkansas

  • Preferred Research Partners /ID# 273128

    Little Rock, Arkansas

  • Hope Clinical Research /ID# 257867

    Canoga Park, California

  • Axiom Research /ID# 257833

    Colton, California

  • Neuro Pain Research Center /ID# 257155

    Fresno, California

  • Axiom Research, LLC-Los Angeles /ID# 264085

    Glendale, California

  • Sun Valley Research Center /ID# 257152

    Imperial, California

  • Axiom Research - Irvine /ID# 264083

    Irvine, California

  • CenExel Collaborative Neuroscience Research /ID# 257828

    Los Alamitos, California

  • BNL Health - Los Angeles Headache Center /ID# 257237

    Los Angeles, California

  • M3 Wake Research - Newport Beach /ID# 257158

    Newport Beach, California

  • Artemis Institute for Clinical Research - San Diego /ID# 257134

    San Diego, California

  • M3 Wake Research - Convoy /ID# 257897

    San Diego, California

  • Optimus Medical /ID# 257856

    San Francisco, California

  • New England Institute for Clinical Research /ID# 264019

    Stamford, Connecticut

  • Neurology Offices of South Florida, PLLC /ID# 257161

    Boca Raton, Florida

  • Accel Research Sites Network - DeLand Clinical Research Unit /ID# 257403

    DeLand, Florida

  • Accel Research Sites - Lakeland Clinical Research Unit /ID# 257874

    Lakeland, Florida

  • Well Pharma Medical Research /ID# 257199

    Miami, Florida

  • Indago Research and Health Center /ID# 277943

    Miami Lakes, Florida

  • Sensible Healthcare /ID# 257198

    Ocoee, Florida

  • Clinical Neuroscience Solutions, Inc /ID# 257190

    Orlando, Florida

  • Conquest Research /ID# 258314

    Winter Park, Florida

  • NeuroTrials Research /ID# 274507

    Atlanta, Georgia

  • Clinical Research Atlanta - Headlands LLC /ID# 260181

    Stockbridge, Georgia

  • Hawaii Pacific Neuroscience /ID# 274469

    Honolulu, Hawaii

  • Velocity Clinical Research - Boise /ID# 257135

    Meridian, Idaho

  • Healthcare Research Network /ID# 257868

    Tinley Park, Illinois

  • Deaconess Midtown Hospital /ID# 257400

    Evansville, Indiana

  • Accellacare - McFarland Clinic /ID# 257834

    Ames, Iowa

  • Alliance for Multispecialty Research LLC /ID# 257839

    Newton, Kansas

  • Collective Medical Research /ID# 257131

    Overland Park, Kansas

  • Alliance For Multispeciality Research - Wichita East /ID# 257148

    Wichita, Kansas

  • Tandem Clinical Research - Marrero - Barataria Boulevard /ID# 260146

    Marrero, Louisiana

Showing 40 of 106 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.